Brazil has evolved strikingly in the last few years in the area of health assistance and access to medicines by its aging and urbanizing population. The government has also set the health industry - which includes pharmaceutical innovation - as one of its strategic sectors to be developed in the...

Brazil has evolved strikingly in the last few years in the area of health assistance and access to medicines by its aging and urbanizing population. The government has also set the health industry - which includes pharmaceutical innovation - as one of its strategic sectors to be developed in the...

Health care, including access to medicines, is granted as a citizen's right by the Brazilian Constitution through a national health system called Unified Health System (SUS). The Pharmaceutical Care Programmes of SUS are, quite often, the only way a large part of the population has to obtain...

The study tried to identify the FSB's and biotechnology researches in another sectoral funds context conditions, operations and results. Moreover, regional distribution of the selected projects was evaluated. Data from MCT, FINEP, Innovation website of MCT, Rais, and IBGE were employed. The...

Two major changes in Brazilian legislation during the 1990s reshaped the local pharmaceutical industry: the ratification of the TRIPS agreement including a provision for pipeline inventions in 1996, and a Generic Drug Act in 1999, which introduced bioequivalence tests and facilitated generic...

This paper tries to build and to analyze the evolution of technological indexes in Brazilian chemical industry during the 1985-2009 period. Our main conclusions are the following: the petrochemical emphasis of this industry has stood by; besides there have been an important technological...

The Covid-19 pandemic exposed the fragility of institutional supply arrangements to the world and sparked predatory competition among buyers. In this context, the rationalization of demand and use of medical inputs and the centralized management o these acquisitions are recommended strategies,...

The text discusses possibilities of public policies for the development of biopharmaceuticals in Brazil, with emphasis on monoclonal antibodies (mAbs). First section discusses the basic concepts about biotechnology, biopharmaceuticals and monoclonal antibodies in order to sustain the later...

Two major changes in Brazilian legislation during the 1990s reshaped the local pharmaceutical industry: the ratification of the TRIPS agreement including a provision for pipeline inventions in 1996, and a Generic Drug Act in 1999, which introduced bioequivalence tests and facilitated generic...